外周血中K-ras和p53基因突变对胃癌术后复发转移的预测价值

李明; 刘燕青; 胡鹏飞

doi:10.3969/j.issn.1671-038X.2018.01.09

外周血中K-ras和p53基因突变对胃癌术后复发转移的预测价值

- 1 荆州市江陵县人民医院, 湖北荆州 434100;
- 2 荆州市第一人民医院, 湖北荆州 434000

详细信息

作者简介:
李明,男,本科,主治医师。研究方向:普外科

通讯作者: 李明,E-mail:limings25@163.com

中图分类号: R735.2

收稿日期: 2017-06-20

Prognostic value of K-ras and p53 gene mutations in peripheral blood for postoperative recurrence and metastasis of gastric cancer

- 1 Jiangling County People's Hospital, Hubei, Jingzhou 434100, China;
- 2 First People's Hospital of Jingzhou, Hubei, Jingzhou 434000, China

More Information

Corresponding author: LI Ming, E-mail: limings25@163.com

Received Date: 20 June 2017

摘要

摘要: [目的]探讨外周血K-ras和p53基因突变对胃癌根治术患者术后复发转移的预测价值。[方法]纳入2010年1月±013年12月于我院接受胃癌根治术的107例患者为对象, 对其持续随访, 并分别于化疗前后取外周血标本。另于2017年3月~5月募集健康志愿者38例, 取外周血标本。采用聚合酶链反应-单链构象多态性分析 (PCR-SSCP) 技术检测标本K-ras和p53基因突变情况。观察上述基因突变与胃癌患者临床病理特征及复发转移的关系。[结果]107例患者中, 共54例复发转移, 发生率50.47%;化疗前p53基因突变30例, 占28.04%, K-ras基因突变35例, 占32.71%。健康志愿者均未能检出p53与K-ras基因突变。K-ras与p53基因突变受化疗影响较轻, 且与性别、年龄、手术方案等临床资料无明显关系 (P＞0.05)。化疗前外周血中检出p53和K-ras基因突变的患者术后无病生存时间明显更短 (P＜0.05), 两基因突变均是患者术后复发转移的独立危险因素 (OR=3.785, 2.983;P＜0.05)。化疗前K-ras基因突变对预测复发转移的敏感度0.556、特异度0.906;化疗前p53基因突变对预测复发转移的敏感度0.481、特异度0.924。[结论]胃癌根治术患者术后化疗前外周血中K-ras和p53基因突变检出率较高, 且存在上述基因突变患者更易出现复发转移。
- K-ras /
- p53 /
- 基因突变 /
- 胃癌 /
- 复发转移
Abstract: [Objective] To investigate the prognostic value of peripheral blood K-ras and p53 gene mutations for cancer recurrence and metastasis in patients with gastric cancer after radical resection.[Methods] 107 patients with gastric cancer treated with radical resection from January 2010 to December 2013 were involved and followed up.Their peripheral blood were sampled before and after chemotherapy respectively.In addition, 38 healthy volunteers were collected from March to May in 2017, whose peripheral blood samples were taken during medically examination.The K-ras and p53 gene mutations in specimens were detected by Polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP).The relationship between the gene mutation and clinicopathological features, recurrence and metastasis in patients with gastric cancer were observed.[Results] 54 out of the involved 107 cases were observed recurrence and metastasis, the incidence rate was 50.47%.Before chemotherapy, p53 gene mutation was found in 30 cases (28.04%).K-ras gene mutation was found in 35 cases (32.71%).No p53 and K-ras gene mutation was found in healthy volunteers.K-ras and p53 gene mutations were rarely affected by chemotherapy, and were not significantly related to gender, age, surgical protocol and other clinical data (P＞0.05).Disease free survival time wassignificantly shorter in patients with p53 or K-ras gene mutation before chemotherapy (P＜0.05).These two mutations were independent risk factors for recurrence and metastasis after surgery (OR=3.785, 2.983;P＜0.05).The sensitivity and specificity for predicting recurrence and metastasis by K-ras gene mutation was 0.556 and 0.906, by p53 gene mutation was 0.481 and 0.924.[Conclusion] Patients with radical gastrectomy has a high detection rate of K-ras and p53 gene mutation in peripheral blood.K-ras and p53 gene mutations are predictors for the inclination of recurrence and metastasis.
- K-ras /
- p53 /
- Gene mutation /
- Gastric cancer /
- Recurrence and metastasis

HTML全文

参考文献(15)

[1]	Karimi P, Islami F, Anandasabapathy S, et al.Gastric cancer:descriptive epidemiology, risk factors, screening, and prevention[J].Cancer Epidemiol Biomarkers Prev, 2014, 23 (5):700-713.
[2]	张学伟, 郑安斌, 石炜, 等.胃癌根治术后复发转移的影响因素及其对预后的影响[J].实用癌症杂志, 2015, 30 (7):1062-1064.
[3]	陈舒晨, 张春东, 徐晓阳, 等.胃癌组织Ki-67表达与复发转移相关性分析[J].中华肿瘤防治杂志, 2014, 21 (18):1423-1428.
[4]	刘珊, 程波, 钟善传, 等.结直肠癌K-ras基因突变与Ras、EGFR、p53蛋白表达的相关性[J].诊断病理学杂志, 2014, 21 (2):90-93.
[5]	陕飞, 李子禹, 张连海, 等.国际抗癌联盟及美国肿瘤联合会胃癌TNM分期系统 (第8版) 简介及解读[J].中国实用外科杂志, 2017, 37 (1):15-17.
[6]	龚巍巍, 罗胜兰, 胡如英, 等.2005-2010年浙江省胃癌生存率分析[J].中华肿瘤杂志, 2014, 36 (8):636-639.
[7]	Nashimoto A, Akazawa K, Isobe Y, et al.Gastric cancer treated in 2002in Japan:2009annual report of the JGCA nationwide registry[J].Gastric Cancer, 2013, 16 (1):1-27.
[8]	Walther W, Schlag PM.Current status of gene therapy for cancer.Curr Opin Oncol[J].2013, 25 (6):659-664.
[9]	van Grieken NC, Aoyama T, Chambers PA, et al.KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West:results from a large international multicentre study[J].Br J Cancer, 2013, 108 (7):1495-1501.
[10]	Busuttil RA, Zapparoli GV, Haupt S, et al.Role of p53 in the progression of gastric cancer[J].Oncotarget, 2014, 5 (23):12016-12026.
[11]	黄荧, 魏嘉, 刘宝瑞.K-ras突变在胃癌预后及靶向治疗中的研究进展[J].中华肿瘤杂志, 2016, 38 (2):81-85.
[12]	王晓龙, 张成武, 刘宁, 等.P53基因Arg72Pro单核苷酸多态性与青海地区人群胃癌易感性的相关性分析[J].中国免疫学杂志, 2014, 30 (2):178-181.
[13]	徐燕, 蔡媛, 荆娟, 等.胃癌组织中HER2基因及p53蛋白表达及其临床意义[J].现代生物医学进展, 2016, 16 (24):4750-4752.
[14]	赵丹, 龚光伟, 李胜文, 等.胃癌根治术后复发类型及影响因素分析[J].实用癌症杂志, 2013, 28 (3):278-281.
[15]	Kang WM, Meng QB, Yu JC, et al.Factors associated with early recurrence after curative surgery for gastric cancer[J].World J Gastroenterol, 2015, 21 (19):5934-5940.